Home » News » Drug Sponsors » Zenobia partners with Alzheimer’s Drug Discovery Foundation

Zenobia partners with Alzheimer’s Drug Discovery Foundation

Wednesday, August 15, 2012

Zenobia Therapeutics, a fragment-based discovery company focused on central nervous system (CNS) disease based in San Diego, has formed a strategic partnership to provide Alzheimer’s Drug Discovery Foundation (ADDF) researchers access to Zenobia’s discovery platform.

Zenobia will provide ADDF researchers with complementary consultation to establish joint research plans that utilize the Zenobia platform and assist in preparation of grant proposals. Once funded, Zenobia will continue to work closely with researchers to evolve the plans as the program progresses. In addition, Zenobia will offer their premier Fragment Library 1 at a reduced price to ADDF researchers.

The Zenobia platform includes: a gene-to-structure platform with in-house cloning, expression and purification in E coli, insect and mammalian cells, a custom fragment library composed of diverse cores suitable for discovery of lead compounds that cross the blood-brain barrier, fragment screening by multiple validated methods and assay development (enzyme, cell and Drosophila). Zenobia will also provide access to their internal medicinal chemistry expertise to optimize the fragments to leads that are potent, selective and optimized for CNS ADME/PK properties.

Related Posts